The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
-
Local Institution - 0050, Scottsdale, Arizona, United States, 85253
Local Institution - 0017, Aurora, Colorado, United States, 80045
Local Institution - 0015, Tampa, Florida, United States, 33612
Local Institution - 0016, Kansas City, Kansas, United States, 66160
Local Institution - 0049, Foxboro, Massachusetts, United States, 02035
Local Institution - 0018, Saint Louis, Missouri, United States, 63110
Local Institution - 0002, Cincinnati, Ohio, United States, 45219
Hope Neurology, Knoxville, Tennessee, United States, 37922
Local Institution - 0001, Kirkland, Washington, United States, 98034
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 70 Years
ALL
No
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2027-01-27